The price of Karyopharm Therapeutics Inc (NASDAQ: KPTI) closed at $1.22 in the last session, down -8.96% from day before closing price of $1.34. On the day, 1391688 shares were traded.
Ratios:
We take a closer look at KPTI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.32 and its Current Ratio is at 3.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on January 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $8.
On November 04, 2022, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $7 to $10.
JP Morgan Upgraded its Underweight to Neutral on February 09, 2022, while the target price for the stock was maintained at $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 04 ’24 when Paulson Richard A. sold 3,563 shares for $1.29 per share. The transaction valued at 4,596 led to the insider holds 1,157,273 shares of the business.
Paulson Richard A. sold 3,573 shares of KPTI for $4,645 on Mar 05 ’24. The President and CEO now owns 1,160,836 shares after completing the transaction at $1.30 per share. On Mar 01 ’24, another insider, Paulson Richard A., who serves as the President and CEO of the company, sold 19,374 shares for $1.20 each. As a result, the insider received 23,249 and left with 1,164,409 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.96.
Stock Price History:
Over the past 52 weeks, KPTI has reached a high of $4.87, while it has fallen to a 52-week low of $0.62.
Shares Statistics:
A total of 114.92M shares are outstanding, with a floating share count of 105.74M. Insiders hold about 8.11% of the company’s shares, while institutions hold 66.37% stake in the company.
Earnings Estimates
The company has Karyopharm Therapeutics Inc. analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $31.23, with high estimates of $0.00 and low estimates of $28.52.
